First Time Loading...

Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 3.75 GBX Market Closed
Updated: Apr 26, 2024

Operating Margin
Fusion Antibodies PLC

-191.3%
Current
-64%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-191.3%
=
Operating Profit
-3m
/
Revenue
1.6m

Operating Margin Across Competitors

Operating Margin Comparison
Fusion Antibodies PLC Competitors

Country Company Market Cap Operating
Margin
UK
Fusion Antibodies PLC
LSE:FAB
3.6m GBP
-191%
US
Thermo Fisher Scientific Inc
NYSE:TMO
221.6B USD
17%
US
Danaher Corp
NYSE:DHR
181.8B USD
22%
US
IQVIA Holdings Inc
NYSE:IQV
42.6B USD
14%
CH
Lonza Group AG
SIX:LONN
37.9B CHF
20%
US
Agilent Technologies Inc
NYSE:A
40.3B USD
19%
KR
Samsung Biologics Co Ltd
KRX:207940
54.8T KRW
30%
US
Mettler-Toledo International Inc
NYSE:MTD
26.8B USD
29%
US
West Pharmaceutical Services Inc
NYSE:WST
26.8B USD
24%
IE
ICON PLC
NASDAQ:ICLR
25.4B USD
13%
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.9B EUR
15%
Fusion Antibodies PLC
LSE:FAB
Country UK
Market Cap 3.6m GBP
Operating Margin
-191%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 221.6B USD
Operating Margin
17%
Danaher Corp
NYSE:DHR
Country US
Market Cap 181.8B USD
Operating Margin
22%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 42.6B USD
Operating Margin
14%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 37.9B CHF
Operating Margin
20%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 40.3B USD
Operating Margin
19%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 54.8T KRW
Operating Margin
30%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 26.8B USD
Operating Margin
29%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 26.8B USD
Operating Margin
24%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 25.4B USD
Operating Margin
13%
Sartorius Stedim Biotech SA
PAR:DIM
Country FR
Market Cap 18.9B EUR
Operating Margin
15%

Profitability Report

View the profitability report to see the full profitability analysis for Fusion Antibodies PLC.

Full Profitability Report

See Also

Summary
FAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
FAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FAB stock valuation using valuation multiples.
Wall Street Estimates
FAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-191.3%
=
Operating Profit
-3m
/
Revenue
1.6m
What is the Operating Margin of Fusion Antibodies PLC?

Based on Fusion Antibodies PLC's most recent financial statements, the company has Operating Margin of -191.3%.

ALPHA SPREAD
Join more than 131,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.